Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial

JAMA

Volumn 305, Issue 6, 2011, Pages 569-575

  Giuliano, Armando E ^a   Hunt, Kelly K ^b   Ballman, Karla V ^c   Beitsch, Peter D ^d   Whitworth, Pat W ^e   Blumencranz, Peter W ^f   Leitch, A Marilyn ^g   Saha, Sukamal ^h   McCall, Linda M ⁱ   Morrow, Monica ^j  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d Dallas Surgical Group   (United States)

^e Nashville Breast Center   (United States)

^f Morton Plant Hospital   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MICHIGAN STATE UNIVERSITY   (United States)

ⁱ American College of Surgeons Oncology Group   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AGE; ARTICLE; AXILLARY LYMPH NODE EXTIRPATION; AXILLARY WEB SYNDROME; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PARESTHESIA; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SEROMA; SHOULDER PAIN; STAINING; SURGICAL INFECTION; WEAKNESS;

EID: 79751522951     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.90     Document Type: Article

References (40)

1. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1-19.
2. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet. 1981;152(6):765-772. (Pubitemid 11072899)
3. Graversen HP, Blichert-Toft M, Andersen JA, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol. 1988;14(5):407-412. (Pubitemid 18263429)
4. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575.
5. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol. 1999;6(1):109-116. (Pubitemid 29077496)
6. Clarke M, Collins R, Darby S, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087- 2106. (Pubitemid 41797643)
7. Yeoh EK, Denham JW, Davies SA, Spittle MF. Primary breast cancer: complications of axillary management. Acta Radiol Oncol. 1986;25(2):105-108. (Pubitemid 16061671)
8. Lotze MT, Duncan MA, Gerber LH, Woltering EA, Rosenberg SA. Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg. 1981;193(3):288-295. (Pubitemid 11154123)
9. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66(1):136-138.
10. Lucci A, McCall LM, Beitsch PD, et al; American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011. J Clin Oncol. 2007;25(24):3657-3663. (Pubitemid 47372604)
11. Lyman GH, Giuliano AE, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-7720. (Pubitemid 46291835)
12. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer. 2003;3(6):453-458.
13. Abrams JS. Adjuvant therapy for breast cancer - results from the USA consensus conference. Breast Cancer. 2001;8(4):298-304.
14. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998;90(21):1601-1608. (Pubitemid 28523434)
15. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874. (Pubitemid 32878711)
16. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
17. Albain KS, Barlow WE, Shak S, et al; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
18. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734. (Pubitemid 46622311)
19. Swedish Organised Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer. 2007;109(11):2205-2212.
20. Fisher B, Montague E, Redmond C, et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer. 1977;39(6)(suppl):2827- 2839. (Pubitemid 8130398)
21. Rutgers EJ. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol. 2008;26(5):698-702. (Pubitemid 351264381)
22. van la Parra RF, Ernst MF, Bevilacqua JL, et al. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol. 2009;16(5):1128-1135.
23. Amanti C, Lombardi A, Maggi S, et al. Is complete axillary dissection necessary for all patients with positive findings on sentinel lymph node biopsy? validation of a breast cancer nomogram for predicting the likelihood of a non-sentinel lymph node. Tumori. 2009;95(2):153-155.
24. Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27(17):2800-2808.
25. Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol. 2009;16(3):687-696.
26. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(13):822-828. (Pubitemid 19094701)
27. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339 (8785):71-85.
28. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992;339(8784):1-15.
29. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis. 1981;34(9-10):469-479. (Pubitemid 11002122)
30. Kaji AH, Lewis RJ. Are we looking for superiority, equivalence, or noninferiority? asking the right question and answering it correctly. Ann Emerg Med. 2010;55(5):408-411.
31. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-433.
32. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279-293.
33. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553. (Pubitemid 36951366)
34. Veronesi U, Orecchia R, Zurrida S, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16(3):383-388. (Pubitemid 40458313)
35. Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg. 2005;242(1):1-9.
36. Rudenstam CM, Zahrieh D, Forbes JF, et al; International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24(3):337-344. (Pubitemid 46630451)
37. Greco M, Agresti R, Cascinelli N, et al. Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg. 2000;232(1):1-7. (Pubitemid 30456543)
38. Martelli G, Miceli R, Daidone MG, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up [published online ahead of print July 23, 2010]. Ann Surg Oncol. 2010. doi:10.1245/s10434-010-1217-7.
39. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251(4):595-600.
40. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel Members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319-1329.